Rapidx · raw details

RapiDx is developing a self-administered rapid blood diagnostic test capable of extracting an accurate amount of blood with less pain while preventing contamination. Based on RapiDxs proprietary technology, the companys menu of rapid blood diagnostic self- and single-use tests are designed for discreet home use for an array of health conditions. RapiDx has identified the painful lancing process, along with the potential risk of contamination from exposed blood, as one of the main obstacles deterring individuals from performing rapid blood tests. In response, RapiDx has integrated the lancet, blood collection, and RDT into one affordable, completely disposable device. The company is planning to launch a series of rapid blood self-tests to be used by the growing point-of-care (POC) and homecare markets. RapiDx has completed development on its first working prototype. The company has also completed a clinical trial at Tel Aviv Medical Center, with 30 volunteers demonstrating faster blood extraction and less pain compared to the gold-standard technique performed by nurses. The results have led the company to register an FDA 510(k) patent on the novel component of its blood extraction process.